9 pending office actions • 7 clients
| Client (Assignee) | Pending OAs |
|---|---|
| The Trustees of Dartmouth College | 2 |
| BEIJING TIDE PHARMACEUTICAL CO., LTD. | 2 |
| Pharmacosmos Holding A/S | 1 |
| Innate Pharma | 1 |
| Celyad S.A. | 1 |
| Macrogenics, Inc. | 1 |
| Janssen Pharmaceuticals, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18421494 | IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE | Pharmacosmos Holding A/S | PAGANO, ALEXANDER R | 1692 | Final Rejection | Jan 24, 2024 |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | The Trustees of Dartmouth College | MONTANARI, DAVID A | 1632 | Non-Final OA | Nov 13, 2023 |
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | Innate Pharma | HUYNH, PHUONG N | 1641 | Non-Final OA | Oct 20, 2023 |
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | Celyad S.A. | MOSELEY II, NELSON B | 1642 | Non-Final OA | Mar 24, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Macrogenics, Inc. | BUNNER, BRIDGET E | 1647 | Non-Final OA | Mar 06, 2023 |
| 18163374 | ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY | The Trustees of Dartmouth College | DAHLE, CHUN WU | 1641 | Non-Final OA | Feb 02, 2023 |
| 18045525 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Janssen Pharmaceuticals, Inc. | OUSPENSKI, ILIA I | 1644 | Non-Final OA | Oct 11, 2022 |
| 17607438 | METHOD FOR TREATING COUGH BY USING DIAMINOPYRIMIDINE COMPOUND | BEIJING TIDE PHARMACEUTICAL CO., LTD. | PECKHAM, RICHARD GRANT | 1627 | Non-Final OA | Oct 29, 2021 |
| 17367726 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. | HABTE, KAHSAY | 1624 | Non-Final OA | Jul 06, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial